Synergies for Cancer Treatment
Pages
Home
Theory
Ammonia
Synergies
Drug Repurposing
Spreadsheet
GBM
TNBC
Herbs
Forum
Reading list
FAQ
Terms
Pages
Warburg Effect
Bohr Effect
Hoffman Effect
Cellular respiration
Urea Cycle
Cell signalling
p53 pathway
Diet
Safe Use
Sitemap
About
Healing Sounds ♫
Natural tuning:
https://www.432player.com
For best results listen with headphones. Do not listen while driving.
1.
Solfeggio frequencie
s
:
UT – 396 Hz – Liberating Guilt and Fear
RE – 417 Hz – Undoing Situations and Facilitating Change
MI – 528 Hz – Transformation and Miracles
FA – 639 Hz – Connecting/Relationships
SOL – 741 Hz – Awakening Intuition
LA – 852 Hz – Returning to Spiritual Order
2.
Brainwaves, Binaural Beats and Isochronic Tones
References and Sources
Music as a pharmaceutical alternative {ref}
Pineal Gland and Cancer—An Epigenetic Approach to the Control of Malignancy: Evaluation of the Role of Melatonin
https://www.mindamend.com/brainwave-entrainment/isochronic-tones/
No comments:
Post a Comment
Home
Subscribe to:
Posts (Atom)
Drug Repurposing Strategies in Oncology
Drug Repurposing Drug repurposing involves discovering new uses for existing, clinically approved drugs. This approach offers several key ad...
Theory of Cancer
According to the prevailing accepted theory of carcinogenesis { ref }, the somatic mutation theory, cancer arises when cells acquire many ge...
Synergistic Anticancer Effects of Diclofenac and Metformin
Repurposing non-oncology drugs for cancer treatment has become an area of increasing interest. In particular, combinations of well-known pha...
Repurposing Phenylbutyrate: versatile anticancer agent
Phenylbutyrate (PB), a short-chain fatty acid derivative, is primarily recognized as an ammonia scavenger and histone deacetylase inhibitor ...
Combination of RAS(ON) G12C-selective inhibitors with SHP2 inhibitors to sensitize tumours to immune checkpoint blockade
Lung cancer driven by KRAS mutations, particularly the G12C variant, remains a significant challenge in non-small cell lung cancer (NSCLC) t...
No comments:
Post a Comment